Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
M MUSCULO-SKELETAL SYSTEM
M05 DRUGS FOR TREATMENT OF BONE DISEASES
M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
M05BA Bisphosphonates
M05BA07 Risedronic acid
D03234 Sodium risedronate hydrate (JP18) <JP/US>
USP drug classification [BR:br08302]
Metabolic Bone Disease Agents
Bisphosphonates
Risedronate
D03234 Sodium risedronate hydrate (JP18)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D03234 Sodium risedronate hydrate (JP18)
Drug groups [BR:br08330]
Musculo-skeletal system agent
DG03232 Osteoporosis agent
DG01600 Bisphosphonate
DG00786 Risedronic acid
D03234 Sodium risedronate hydrate
Drug classes [BR:br08332]
Musculo-skeletal system agent
DG03232 Osteoporosis agent
D03234 Sodium risedronate hydrate
Target-based classification of drugs [BR:br08310]
Enzymes
Transferases (EC2)
Alkyl/Aryl transferases
FDPS
D03234 Sodium risedronate hydrate (JP18) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D03234 Sodium risedronate hydrate
D03234 Sodium risedronate tablets
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03234
Drug groups [BR:br08330]
Musculo-skeletal system agent
DG03232 Osteoporosis agent
DG01600 Bisphosphonate
DG00786 Risedronic acid